Wesley Wade Jackson

Address:

617 E Gates St, Columbus, OH 43206

VIN:

2CNDL13F276093258

Make:

CHEVROLET

Model:

EQUINOX

Year:

2007

US Patent:

20110318414, Dec 29, 2011

Filed:

Aug 5, 2009

Appl. No.:

13/129636

Inventors:

Wesley M. Jackson - Albany CA, US
Leon J. Nesti - Silver Spring MD, US
Rocky S. Tuan - Bethesda MD, US

International Classification:

A61K 35/12
C12N 5/077
A61P 29/00
A61P 31/00
A61P 25/00
A61P 9/00
A61P 19/08
A61F 2/28
A61F 2/02
A61P 31/12
B82Y 5/00

US Classification:

424484, 424 937, 435378, 435379, 424400, 623 2372, 977762, 977906

Abstract:

A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.

US Patent:

20210113702, Apr 22, 2021

Filed:

Aug 5, 2020

Appl. No.:

16/985522

Inventors:

- Oakland CA, US
Eda Isil Altiok - Berkeley CA, US
David V. Schaffer - Danville CA, US
Wesley M. Jackson - Albany CA, US

International Classification:

A61K 47/61
A61K 9/00
A61K 38/16
A61K 47/32
A61K 47/36
A61K 9/06
A61K 38/17
A61K 47/69
C07K 16/22
A61K 38/43
A61K 39/395

Abstract:

The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.

US Patent:

20180318431, Nov 8, 2018

Filed:

Dec 8, 2016

Appl. No.:

15/781395

Inventors:

- Oakland CA, US
Eda Isil Altiok - Berkeley CA, US
David V. Schaffer - Danville CA, US
Wesley M. Jackson - Albany CA, US

International Classification:

A61K 47/61
A61K 9/00
A61K 38/43
A61K 39/395

Abstract:

The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.

US Patent:

20160155355, Jun 2, 2016

Filed:

Feb 8, 2016

Appl. No.:

15/017928

Inventors:

- San Francisco CA, US
HYUN KYU LEE - South San Francisco CA, US
CHUNG-HAY LUK - Walnut Creek CA, US
MOR NAHUM - San Francisco CA, US
JYOTI MISHRA RAMANATHAN - San Francisco CA, US
HENRY W. MAHNCKE - San Francisco CA, US
THOMAS MATTHEW VAN VLEET - El Cerrito CA, US
TRAVIS WILLIAM WADE - San Francisco CA, US
PETER BRENDAN DELAHUNT - San Mateo CA, US
JEFFERSON ARTHUR DEWEY - San Francisco CA, US
SAMUEL CHUNGCHI CHAN - Alameda CA, US
GREGORY MICHAEL SABATINI - Richmond CA, US
DONALD KELLY RICHARDS - Lagunitas CA, US
WESLEY MARSHALL JACKSON - Daly City CA, US

International Classification:

G09B 19/00
G09B 5/06

Abstract:

A game delivery system delivers a plurality of games in a training program. The training program is configured to systematically drive neurological changes to overcome cognitive deficits associated with a neurological disorder. In one embodiment, the training program includes an initial batch of games that predominantly exercise elemental, lower-level cognitive processes and sensory deficits. After a game participant progresses through the initial batch of games, the training program provides games that impose comparatively greater higher-order cognitive processing requirements on the participant. A clinician portal provides remote access to a clinician to data about the game participant's compliance and performance with the training program. The clinician portal also enables the administrator to configure the training program.

US Patent:

20160053029, Feb 25, 2016

Filed:

Apr 1, 2014

Appl. No.:

14/780447

Inventors:

- Oakland CA, US
Eda Isil ALTIOK - Berkeley CA, US
Wesley M. JACKSON - Albany CA, US
Kevin E. HEALY - Moraga CA, US

International Classification:

C08B 37/08
A61K 35/36
A61K 35/30
A61K 35/34
A61K 9/48
A61K 35/545

Abstract:

The present disclosure provides methods for sulfonation of hyaluronic acid. The present disclosure provides sulfonated hyaluronic acid, and compositions, including pharmaceutical compositions, comprising the sulfonated hyaluronic acid. The present disclosure provides implantable materials and drug delivery compositions comprising a subject sulfonated hyaluronic acid.

US Patent:

20140227339, Aug 14, 2014

Filed:

Feb 12, 2014

Appl. No.:

14/178932

Inventors:

Wesley M. Jackson - Albany CA, US
Leon J. Nesti - Silver Spring MD, US
Rocky S. Tuan - Bethesda MD, US

Assignee:

THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. - Bethesda MD
THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF - Rockville MD
THE UNITED STATES GOVERNMENT, AS REPRESENTED BY THE SECRETARY OF THE ARMY, U.S.A. - Fort Detrick MD

International Classification:

A61K 9/70
A61K 45/06
A61K 35/28

US Classification:

424443, 424 937, 435325, 435378

Abstract:

A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.